172 related articles for article (PubMed ID: 28125371)
21. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
Hwang TJ; Kesselheim AS; Tibau A; Lee CC; Vokinger KN
JCO Oncol Pract; 2022 Sep; 18(9):e1522-e1532. PubMed ID: 35731996
[TBL] [Abstract][Full Text] [Related]
22. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
Michaeli DT; Mills M; Kanavos P
Appl Health Econ Health Policy; 2022 Sep; 20(5):757-768. PubMed ID: 35821360
[TBL] [Abstract][Full Text] [Related]
23. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
[TBL] [Abstract][Full Text] [Related]
24. Patient access to pharmaceuticals: an international comparison.
Cohen J; Faden L; Predaris S; Young B
Eur J Health Econ; 2007 Sep; 8(3):253-66. PubMed ID: 17279403
[TBL] [Abstract][Full Text] [Related]
25. A Time-Trend Economic Analysis of Cancer Drug Trials.
Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
[TBL] [Abstract][Full Text] [Related]
26. Product director clarifies point about Medicare coverage of oral anticancer drugs.
Kaiser GM
ONS News; 2005 Apr; 20(4):3; author reply 3. PubMed ID: 15862044
[No Abstract] [Full Text] [Related]
27. Medicare Spending on Drugs With Accelerated Approval.
Ballreich J; Socal M; Bennett CL; Schoen MW; Trujillo A; Xuan A; Anderson G
Ann Intern Med; 2022 Jul; 175(7):938-944. PubMed ID: 35605235
[TBL] [Abstract][Full Text] [Related]
28. New drug approval times and 'therapeutic potential' in Canada, Australia, Sweden and the United States during the period 1992 to 1998.
Rawson NS; Kaitin KI
Can J Clin Pharmacol; 2000; 7(2):97-101. PubMed ID: 10958705
[TBL] [Abstract][Full Text] [Related]
29. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.
Chambers JD; Pope EF; Wilkinson CL; Neumann PJ
J Manag Care Spec Pharm; 2018 Dec; 24(12):1240-1246. PubMed ID: 30479201
[TBL] [Abstract][Full Text] [Related]
30. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
Jacquet E; Kerouani-Lafaye G; Grude F; Goncalves S; Lorence A; Turcry F; Brunel L; Belgodere L; Monard A; Guyader G; Boudali L; Albin N
Eur J Cancer; 2021 May; 149():82-90. PubMed ID: 33838392
[TBL] [Abstract][Full Text] [Related]
31. Prescription Drug Utilization and Reimbursement Increased Following State Medicaid Expansion in 2014.
Mahendraratnam N; Dusetzina SB; Farley JF
J Manag Care Spec Pharm; 2017 Mar; 23(3):355-363. PubMed ID: 28230452
[TBL] [Abstract][Full Text] [Related]
32. Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications.
Kwon HY; Kim H; Godman B
Front Pharmacol; 2018; 9():938. PubMed ID: 30233363
[No Abstract] [Full Text] [Related]
33. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
34. Patient access to new cancer drugs in the United States and Australia.
Wilson A; Cohen J
Value Health; 2011; 14(6):944-52. PubMed ID: 21914517
[TBL] [Abstract][Full Text] [Related]
35. Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017.
Skydel JJ; Egilman AC; Wallach JD; Ramachandran R; Gupta R; Ross JS
JAMA Health Forum; 2022 May; 3(5):e221158. PubMed ID: 35977252
[TBL] [Abstract][Full Text] [Related]
36. Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020.
Outterson K; Orubu ESF; Rex J; Årdal C; Zaman MH
Clin Infect Dis; 2022 Apr; 74(7):1183-1190. PubMed ID: 34251436
[TBL] [Abstract][Full Text] [Related]
37. How does drug coverage vary by insurance type? Analysis of drug formularies in the United States.
Régnier SA
Am J Manag Care; 2014 Apr; 20(4):322-31. PubMed ID: 24884863
[TBL] [Abstract][Full Text] [Related]
38. Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration.
Modi ND; Abuhelwa AY; McKinnon RA; Boddy AV; Haseloff M; Wiese MD; Hoffmann TC; Perakslis ED; Rowland A; Sorich MJ; Hopkins AM
JAMA Oncol; 2022 Sep; 8(9):1310-1316. PubMed ID: 35900732
[TBL] [Abstract][Full Text] [Related]
39. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
[TBL] [Abstract][Full Text] [Related]
40. Tackling Cost: A Prescription for Spending Wisely.
Tempero M
J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
